Hebei Medical University Fourth Hospital

This study tests whether the drug adebrelizumab can help prevent esophageal cancer from returning after surgery. About 142 adults who had their cancer completely removed will receive either adebrelizumab or a placebo. The goal is to see if the drug improves how long people stay c…

This study tests two different chemotherapy combinations given before surgery for people with triple-negative breast cancer. The goal is to see which combo works better at shrinking tumors, making surgery easier and more effective. About 520 participants will be randomly assigned…

This study tests two different chemotherapy drug combinations in people with advanced triple-negative breast cancer, a fast-growing type. The goal is to see which combo works better at controlling the disease and extending life. Participants will receive either nab-paclitaxel plu…

This study is testing whether adding bevacizumab to standard chemotherapy before surgery can help shrink tumors in people with early or locally advanced HER2-negative breast cancer. About 75 participants will receive the combination treatment, and researchers will measure how man…

This study tests whether giving a single dose of radiation during breast-conserving surgery can lower the chance of cancer coming back and improve how the breast looks afterward. It involves 620 women aged 55 or older with early-stage, HER2-negative breast cancer. The approach co…

This study tests whether adding a third drug (entinostat) to a two-drug combination (dalpiciclib and letrozole) before surgery can shrink tumors more effectively in people with HR-positive, HER2-negative early breast cancer. About 60 women will receive either the three-drug or tw…

This study tests a combination of four drugs (iparomlimab, tuvonralimab, apatinib, and irinotecan) in 39 adults with advanced stomach cancer that produces a protein called AFP and has worsened after first-line therapy. The goal is to see if this new mix can shrink tumors or slow …

This study looks at how well and how safely the drug dalpiciclib works for people with a type of advanced breast cancer called HR-positive. Researchers will follow 420 patients who are already taking or about to take dalpiciclib as part of their normal care. The goal is to see ho…

This study compares a new targeted therapy (dalpiciclib plus an aromatase inhibitor) against standard chemotherapy for postmenopausal women with a specific type of early breast cancer (ER-positive, HER2-negative, low growth rate). The goal is to see if the new combo works just as…

This study tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy can shrink tumors and slow disease in people with advanced esophageal cancer that has come back or spread. About 25 adults whose cancer cannot be removed by surger…

This study explores whether a drug called trilaciclib can protect the bone marrow in people with solid tumors receiving chemotherapy. The goal is to reduce severe side effects like low blood cell counts. Researchers will develop a model to predict who benefits most from this prev…

This study looks at whether a medicine called mecapegfilgrastim can help prevent neutropenia (dangerously low white blood cells) in cancer patients after chemotherapy, radiation, or immunotherapy. About 200 adults with solid tumors will receive the injection to see if it reduces …

This study aims to create an early-warning system that predicts organ damage in cancer patients receiving immune checkpoint inhibitor therapy. Researchers will analyze genetic, protein, and metabolic data from 2,000 participants to identify warning signs of side effects in organs…